{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:04:35Z","timestamp":1794002675758,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The publication of this article is generously supported by Soraya Ruben Melamed and the Melamed family of Beverly Hills"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to the curative potential and improvement in progression-free survival (PFS), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered the standard of care for several hematologic malignancies, such as multiple myeloma, and lymphomas. ASCT typically involves support with blood product transfusion. Thus, difficulties arise when Jehovah\u2019s Witness patients refuse blood transfusions. In order to demonstrate the safety of performing \u201cbloodless\u201d ASCT (BL-ASCT), we performed a retrospective analysis of 66 Jehovah's Witnesses patients who underwent BL-ASCT and 1114 non-Jehovah\u2019s Witness patients who underwent transfusion-supported ASCT (TF-ASCT) at Cedars-Sinai Medical Center between January 2000 and September 2018. Survival was compared between the two groups. Transplant-related complications, mortality, engraftment time, length of hospital stay, and number of ICU transfers were characterized for the BL-ASCT group. One year survival was found to be 87.9% for both groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.92). In the BL-ASCT group, there was one death prior to the 30 days post transplant due to CNS hemorrhage, and one death prior to 100 days due to sepsis. Based on our data, BL-ASCT can be safely performed with appropriate supportive measures, and we encourage community oncologists to promptly refer JW patients for transplant evaluation when ASCT is indicated.<\/jats:p>","DOI":"10.1038\/s41409-019-0777-9","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T14:03:00Z","timestamp":1577973780000},"page":"1059-1067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients"],"prefix":"10.1038","volume":"55","author":[{"given":"Alyssa","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Reza Rejali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muni","family":"Rubens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vescio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Merin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Federizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohana","family":"Allred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Legaspi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Leaverton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhona","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Gharapetian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Causin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lopiccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ann Snoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"VanStrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya P.","family":"Linhares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"777_CR1","unstructured":"National Comprehensive Cancer Network Guidelines in Oncology. B Cell Lymphomas (version 2.2018). 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed 13 Nov 2019."},{"key":"777_CR2","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Moreau P. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl J Med. 2017;376:1311\u201320.","journal-title":"N. Engl J Med"},{"key":"777_CR3","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131\u20136.","journal-title":"Blood"},{"key":"777_CR4","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1002\/cncr.26662","volume":"118","author":"N Shah","year":"2012","unstructured":"Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, et al. Durable remission with salvage second auto transplants in patients with multiple myeloma. Cancer. 2012;118:3549\u201355.","journal-title":"Cancer"},{"key":"777_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","volume":"18","author":"VH Jimenez-Zepeda","year":"2012","unstructured":"Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Reece DE, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant. 2012;18:773\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"777_CR6","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Clin Oncol. 2010;28:4184\u201390.","journal-title":"Clin Oncol"},{"key":"777_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/cncr.31677","volume":"125","author":"NS Joseph","year":"2019","unstructured":"Joseph NS, Kaufman JL, Boise LH, Valla K, Almaula DK, Obidike CO, et al. Safety and survival outcomes for bloodless transplantation in patients with myeloma. Cancer. 2019;125:185\u201393.","journal-title":"Cancer"},{"key":"777_CR8","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41409-018-0132-6","volume":"53","author":"R Khan","year":"2018","unstructured":"Khan R, Mott SL, Schultz A, Jethava YS, Tricot G. Bloodless tandem autologous transplant in Jehovah's Witness patients. Bone Marrow Transpl. 2018;53:1428\u201333.","journal-title":"Bone Marrow Transpl"},{"key":"777_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/sj.bmt.1700920","volume":"20","author":"BJ Bolwell","year":"1997","unstructured":"Bolwell BJ, Goormastic M, Andresen S, Overoyer B, Pohlman B, Kalaycio M. Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count. Bone Marrow Transpl. 1997;20:459\u201363.","journal-title":"Bone Marrow Transpl"},{"key":"777_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.hemonc.2018.11.003","volume":"12","author":"A Coltoff","year":"2019","unstructured":"Coltoff A, Shreenivas A, Afshar S, Steinberg A. A single-institution experience of performing bloodless transplant in Jehovah\u2019s Witness patients. Hematol Oncol Stem Cell Ther. 2019;12:44\u20139.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"777_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/bmj.322.7277.37","volume":"322","author":"O Muramoto","year":"2001","unstructured":"Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses. Br Med J. 2001;322:37\u20139.","journal-title":"Br Med J"},{"key":"777_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1136\/jme.26.5.375","volume":"26","author":"E Lee","year":"2000","unstructured":"Lee E. Why some Jehovah\u2019s Witnesses accept blood and conscientiously reject official Watchtower Society blood policy. J Med Ethics. 2000;26:375\u201380.","journal-title":"J Med Ethics"},{"key":"777_CR13","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1200\/JCO.2014.57.9912","volume":"33","author":"PA Ford","year":"2015","unstructured":"Ford PA, Grant SJ, Mick R, Keck G. Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. J Clin Oncol. 2015;33:1674\u20139.","journal-title":"J Clin Oncol"},{"key":"777_CR14","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1200\/JCO.2004.01.144","volume":"22","author":"KK Ballen","year":"2004","unstructured":"Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol. 2004;22:4087\u201394.","journal-title":"J Clin Oncol"},{"key":"777_CR15","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004;22:1460\u20138.","journal-title":"J Clin Oncol"},{"key":"777_CR16","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.bbmt.2013.05.019","volume":"19","author":"A Singla","year":"2013","unstructured":"Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:1233\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"777_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bmt.1705246","volume":"37","author":"H Wandt","year":"2006","unstructured":"Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transpl. 2006;37:387\u201392.","journal-title":"Bone Marrow Transpl"},{"key":"777_CR18","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","volume":"368","author":"SJ Stanworth","year":"2013","unstructured":"Stanworth SJ, Estcourt LJ, Powter G, Kahan B, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N. Engl J Med. 2013;368:1771\u201380.","journal-title":"N. Engl J Med"},{"key":"777_CR19","unstructured":"American Society of Clinical Oncology. ASCO Guidelines [Internet]. American Society of Clinical Oncology. 2017. Available from:  https:\/\/www.asco.org\/sites\/new-www.asco.org\/files\/content-files\/2017-platelet-transfusion-slides.pdf. Accessed 13 Nov 2019."},{"key":"777_CR20","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/bjh.12284","volume":"5","author":"C Al-Nawakil","year":"2013","unstructured":"Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, et al. Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. Br J Haematol. 2013;5:738\u20134020.","journal-title":"Br J Haematol"},{"key":"777_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4137\/CMBD.S38461","volume":"9","author":"S Moradi","year":"2016","unstructured":"Moradi S, Jahanian-Najafabadi A, Roudkenar MH. Artificial blood substitutes: first steps on the long route to clinical utility. Clin Med Insights Blood Disord. 2016;9:33\u201341.","journal-title":"Clin Med Insights Blood Disord"},{"issue":"Suppl 1","key":"777_CR22","first-page":"4926","volume":"130","author":"S Bari","year":"2017","unstructured":"Bari S, Rabinovich M, Curry M, Jain SR, Cafuir L. Use of hemoglobin based oxygen carrier HBOC-021 (Hemopure) as a bridge during emergencies in patients unable to receive blood products: experience at a tertiary care center. Blood. 2017;130(Suppl 1):4926.","journal-title":"Blood."},{"key":"777_CR23","first-page":"e30610","volume":"5","author":"JA Posluszny","year":"2016","unstructured":"Posluszny JA, Napolitano LM. Hemoglobin-based oxygen carrier for traumatic hemorrhagic shock treatment in a Jehovah's Witness. Arch Trauma Res. 2016;5:e30610.","journal-title":"Arch Trauma Res"},{"key":"777_CR24","unstructured":"Pew Research Center. Religious Landscape Study [Internet]. Lipka M. A closer look at Jehovah\u2019s Witnesses living in the U.S. April 26, 2016. Available from: https:\/\/www.pewresearch.org\/fact-tank\/2016\/04\/26\/a-closer-look-at-jehovahs-witnesses-living-in-the-u-s\/. Accessed 13 Nov 2019."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0777-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0777-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0777-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:16:34Z","timestamp":1684617394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0777-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0777-9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"10 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}